# Recent trends in the number of patients with pathology samples indicating cancer in Northern Ireland

April 2022 update

### **Further information**

Further information is available at: www.qub.ac.uk/research-centres/nicr **Phone:** +44 (0)28 9097 6028 **e-mail:** nicr@qub.ac.uk

### **Acknowledgements**

The Northern Ireland Cancer Registry (NICR) is funded by the Public Health Agency and is based in Queen's University, Belfast.

NICR uses data provided by patients and collected by the health service as part of their care and support.







# **CONTENTS**

	<u>Page</u>
Summary	1
All persons	4
Males	6
Females	8
Ages 0-69	10
Ages 70 and over	12
Bowel cancer	14
Bowel cancer, screening age	16
Lung cancer	18
Female breast cancer	20
Female breast cancer, screening age	22
Prostate cancer	24
Upper gastrointestinal cancer	26
Gynaecological cancer	28
Head & neck cancer	30
Urinary cancer	32
Haematological cancer	34
Malignant melanoma	36
Non-melanoma skin cancer	38
Other cancer	40
Notes	42

# **SUMMARY**

# Recent trends in the number of patients with pathology samples indicating cancer: April 2022


This summary provides an overview of recent trends in the number of patients with pathology samples indicating cancer (excluding non-melanoma skin cancer, NMSC) whose first sample was taken from January 2020 to April 2022 in Northern Ireland.

These trends are contrasted with the annual average number of patients with pathology samples indicating cancer (ex NMSC) during 2017-2019 in order to provide an indication of the potential impact of the Covid-19 restrictions on diagnostic cancer services.

Data are sourced from the four NHS pathology laboratories in NI (Belfast, Altnagelvin, Antrim, Craigavon), which are usually provided to NICR on a monthly basis. Altnagelvin laboratory is excluded from some analysis as a change in recording systems led to an undercount in the number of reported samples in Jan-Apr 2021.


# CHANGE IN THE NUMBER OF PATIENTS SINCE MARCH 2020 (Excludes Altnagelvin)

From March 2020 to April 2022 the number of patients with a pathological sample indicating cancer (ex NMSC) was 5.0% lower than the average number for the same time period in 2017-2019.




From March 2020 to April 2022 there was a 5.4% decrease among males and a 4.5% decrease among females compared to the same time period in 2017-2019. A decrease of 6.0% occurred in the number of patients aged 0-69 years, while there was a decrease of 3.5% among those aged 70 and older.

Compared to the annual average in 2017-2019, from March 2020 to April 2022 the number of patients with a pathology sample indicating lung cancer decreased by 21.4%. Increases were recorded for bowel cancer, female breast cancer and haematological cancer, while decreases of more than 10% were recorded for gynaecological cancer, head and neck cancer, urinary cancer and non-melanoma skin cancer.




### **RECENT CHANGES IN THE NUMBER OF PATIENTS (Includes Altnagelvin)**

There was a 1.5% increase in the number of patients with a pathology sample indicating cancer in the twelve weeks up to 30/04/2022 compared to the average value in the equivalent weeks in 2017-2019.



In the twelve weeks up to 30/04/2022 there was a 5.1% decrease among males and a 7.6% increase among females compared to the same time period in 2017-2019. A decrease of 2.3% occurred in the number of patients aged 0-69 years, while there was an increase of 6.8% among those aged 70 and older.

Compared to the annual average in 2017-2019, in the twelve weeks up to April 2022 the number of patients with a pathology sample indicating lung cancer decreased by 19.3%. Increases were recorded for bowel cancer, female breast cancer, gynaecological cancer, haematological cancer and melanoma, while decreases of more than 10% were recorded for upper gastrointestinal cancer.




# ALL PERSONS: CANCER (EX NMSC)

# CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-






Month first		Year first sa	mple taken	
sample taken	2017-2019*	2020	2021	2022
Jan	658	661	519	570
Feb	553	588	537	573
Mar	610	557	702	667
Apr	579	336	623	539
Мау	688	456	644	
Jun	604	573	695	
Jul	598	540	574	
Aug	607	527	582	
Sep	613	608	624	
Oct	680	569	615	
Nov	635	664	673	
Dec	544	598	568	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average






Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	142	178	
19/02/2022	169	146	
26/02/2022	164	189	
05/03/2022	174	174	
12/03/2022	168	200	
19/03/2022	155	134	
26/03/2022	176	178	
02/04/2022	160	188	
09/04/2022	185	164	
16/04/2022	141	161	
23/04/2022	163	93	
30/04/2022	180	202	

\* Average patients per year rounded to the nearest integer.

# CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-


2019 average -5.4%



Month first		Year first sa	mple taken	
sample taken	2017-2019*	2020	2021	2022
Jan	320	308	232	277
Feb	257	284	257	256
Mar	297	262	361	286
Apr	280	158	282	235
Мау	328	244	321	
Jun	291	282	332	
Jul	280	248	277	
Aug	281	230	277	
Sep	291	275	305	
Oct	320	245	286	
Nov	301	357	332	
Dec	249	297	243	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average

<sup>-5.1%</sup> 




Year first sample taken		
2017-2019*	2022	
68	85	
77	69	
84	88	
84	87	
82	88	
80	53	
85	83	
78	89	
97	68	
64	80	
79	42	
90	87	
	2017-2019* 68 77 84 84 82 80 85 78 97 64 79	

\* Average patients per year rounded to the nearest integer.

# FEMALE: CANCER (EX NMSC)

### CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin


Percentage change from March 2020 to April 2022 compared to expected number based on 2017-2019 average



Month first		Year first sa	mple taken	
sample taken	2017-2019*	2020	2021	2022
Jan	338	353	287	293
Feb	295	304	280	317
Mar	312	295	341	380
Apr	299	178	341	304
Мау	360	212	323	
Jun	313	291	363	
Jul	317	292	297	
Aug	326	297	305	
Sep	322	333	319	
Oct	360	324	329	
Nov	333	307	341	
Dec	295	301	325	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average

<sup>+7.6%</sup> 




Week first sample	Year first sample taken			
taken**	2017-2019*	2022		
12/02/2022	74	93		
19/02/2022	92	77		
26/02/2022	81	101		
05/03/2022	90	87		
12/03/2022	86	112		
19/03/2022	75	81		
26/03/2022	90	95		
02/04/2022	82	98		
09/04/2022	88	96		
16/04/2022	77	81		
23/04/2022	84	51		
30/04/2022	91	115		

\* Average patients per year rounded to the nearest integer.

# AGED 0-69: CANCER (EX NMSC)

# CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-




2019	average

-6.0%

Month first		Year first sa	mple taken	
sample taken	2017-2019*	2020	2021	2022
Jan	387	358	301	315
Feb	327	332	311	308
Mar	354	325	401	392
Apr	332	202	376	284
Мау	384	265	353	
Jun	333	311	373	
Jul	338	282	317	
Aug	341	292	324	
Sep	351	325	355	
Oct	383	326	361	
Nov	349	378	376	
Dec	309	339	322	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average

<sup>-2.3%</sup> 



Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	84	100	
19/02/2022	96	81	
26/02/2022	91	97	
05/03/2022	97	105	
12/03/2022	102	123	
19/03/2022	90	71	
26/03/2022	99	94	
02/04/2022	92	109	
09/04/2022	106	90	
16/04/2022	84	82	
23/04/2022	95	50	
30/04/2022	97	105	


\* Average patients per year rounded to the nearest integer.

# AGED 70+: CANCER (EX NMSC)

# CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin


Percentage change from March 2020 to April 2022 compared to expected number based on 2017-

2019 average -3.5%



Month first		Year first sa	mple taken	
sample taken	2017-2019*	2020	2021	2022
Jan	271	303	218	255
Feb	226	256	226	265
Mar	255	232	301	275
Apr	247	134	247	255
Мау	305	191	291	
Jun	271	262	322	
Jul	259	258	257	
Aug	266	235	258	
Sep	262	283	269	
Oct	297	243	254	
Nov	285	286	297	
Dec	234	259	246	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average



+6.8%

Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	58	78	
19/02/2022	73	65	
26/02/2022	73	92	
05/03/2022	77	69	
12/03/2022	65	77	
19/03/2022	65	63	
26/03/2022	77	84	
02/04/2022	68	79	
09/04/2022	79	74	
16/04/2022	57	79	
23/04/2022	68	43	
30/04/2022	83	97	


\* Average patients per year rounded to the nearest integer.

# **BOWEL CANCER**

### CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-


2019 average +0.2%



Month first		Year first sa	ample taken	
sample taken	2017-2019*	2020	2021	2022
Jan	73	84	66	77
Feb	65	76	80	75
Mar	74	70	84	74
Apr	74	35	97	77
Мау	81	45	86	
Jun	70	70	73	
Jul	67	71	74	
Aug	74	73	87	
Sep	71	82	81	
Oct	75	61	82	
Nov	84	58	80	
Dec	67	71	72	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average

<sup>+3.2%</sup> 



Week first sample	Year first sample taken			
taken**	2017-2019*	2022		
12/02/2022	18	13		
19/02/2022	23	23		
26/02/2022	23	33		
05/03/2022	20	18		
12/03/2022	21	18		
19/03/2022	18	18		
26/03/2022	21	21		
02/04/2022	23	21		
09/04/2022	20	25		
16/04/2022	21	22		
23/04/2022	18	16		
30/04/2022	21	27		


\* Average patients per year rounded to the nearest integer.

# **BOWEL CANCER (SCREENING AGE)**

# CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-2019 average


+1.8%



Month first		Year first sa	ample taken	
sample taken	2017-2019*	2020	2021	2022
Jan	34	41	27	33
Feb	28	31	42	37
Mar	33	42	42	33
Apr	30	14	45	34
Мау	34	17	35	
Jun	27	37	34	
Jul	28	33	34	
Aug	32	18	33	
Sep	31	30	29	
Oct	33	23	36	
Nov	40	28	36	
Dec	27	29	31	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average

<sup>+4.6%</sup> 



Week first sample	Year first san	ıple taken
taken**	2017-2019*	2022
12/02/2022	8	4
19/02/2022	11	10
26/02/2022	8	18
05/03/2022	11	7
12/03/2022	10	4
19/03/2022	7	6
26/03/2022	9	11
02/04/2022	10	11
09/04/2022	10	10
16/04/2022	7	9
23/04/2022	8	11
30/04/2022	9	12


\* Average patients per year rounded to the nearest integer.

# LUNG CANCER

### CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-


2019 average -21.4%



Month first		Year first sa	imple taken	
sample taken	2017-2019*	2020	2021	2022
Jan	51	56	26	32
Feb	43	52	35	36
Mar	43	37	33	35
Apr	44	22	42	36
Мау	53	36	43	
Jun	47	43	39	
Jul	51	39	41	
Aug	49	39	36	
Sep	52	38	46	
Oct	52	34	40	
Nov	50	38	49	
Dec	35	40	29	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average

<sup>-19.3%</sup> 




Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	10	13	
19/02/2022	11	9	
26/02/2022	14	11	
05/03/2022	11	5	
12/03/2022	13	12	
19/03/2022	13	7	
26/03/2022	12	10	
02/04/2022	13	14	
09/04/2022	12	8	
16/04/2022	11	13	
23/04/2022	11	4	
30/04/2022	19	15	

\* Average patients per year rounded to the nearest integer.

# CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-


2019 average +0.3%



Month first		Year first sa	ample taken	
sample taken	2017-2019*	2020	2021	2022
Jan	116	93	121	90
Feb	94	102	97	105
Mar	108	92	125	131
Apr	93	62	116	106
Мау	120	58	122	
Jun	93	89	130	
Jul	101	93	101	
Aug	103	104	89	
Sep	106	118	101	
Oct	116	123	106	
Nov	101	107	112	
Dec	97	103	104	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average






Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	25	30	
19/02/2022	31	20	
26/02/2022	23	40	
05/03/2022	32	29	
12/03/2022	35	42	
19/03/2022	26	25	
26/03/2022	31	32	
02/04/2022	22	39	
09/04/2022	33	41	
16/04/2022	27	26	
23/04/2022	27	12	
30/04/2022	29	42	

\* Average patients per year rounded to the nearest integer.

# FEMALE BREAST CANCER (SCREENING AGE)

# CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-




20	01	9 ;	ave	era	age
	_	6	2	0	1_

Month first		Year first sa	imple taken	
sample taken	2017-2019*	2020	2021	2022
Jan	61	44	67	47
Feb	50	44	61	52
Mar	51	50	84	62
Apr	41	32	68	40
Мау	57	22	66	
Jun	44	35	70	
Jul	52	40	47	
Aug	54	58	45	
Sep	53	65	53	
Oct	62	68	62	
Nov	48	65	52	
Dec	51	55	58	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average





Week first sample	Year first sample taken			
taken**	2017-2019*	2022		
12/02/2022	13	9		
19/02/2022	18	12		
26/02/2022	12	18		
05/03/2022	15	19		
12/03/2022	20	17		
19/03/2022	11	15		
26/03/2022	13	16		
02/04/2022	9	11		
09/04/2022	16	13		
16/04/2022	12	13		
23/04/2022	13	3		
30/04/2022	14	17		


\* Average patients per year rounded to the nearest integer.

# **PROSTATE CANCER**

### CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-2019 average

-4.3%



Month first		Year first sa	imple taken	
sample taken	2017-2019*	2020	2021	2022
Jan	79	75	42	77
Feb	59	62	51	57
Mar	75	67	118	72
Apr	61	40	63	51
Мау	89	78	70	
Jun	69	67	88	
Jul	69	37	39	
Aug	61	39	57	
Sep	58	46	86	
Oct	88	53	60	
Nov	75	137	92	
Dec	53	79	65	

0510312022

~210312022

40

35

30

25

20

15

10

5

0


~210212022

191022022

28/02/022

Number of patients

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average



2610312022

Week first sample taken

19103/2022

2017-2019

0210412022

0910412022

2022

1022 , 61041202 231041202 301041202

-3.9%

Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	17	30	
19/02/2022	23	16	
26/02/2022	16	15	
05/03/2022	25	22	
12/03/2022	23	25	
19/03/2022	22	22	
26/03/2022	25	21	
02/04/2022	15	24	
09/04/2022	27	19	
16/04/2022	14	14	
23/04/2022	22	10	
30/04/2022	26	27	


\* Average patients per year rounded to the nearest integer.

# UPPER GASTROINTESTINAL CANCER

# CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-2019 average


-4.8%



Month first		Year first sa	ample taken	
sample taken	2017-2019*	2020	2021	2022
Jan	31	42	18	26
Feb	24	28	24	25
Mar	29	22	35	30
Apr	28	14	28	18
Мау	26	17	23	
Jun	28	27	36	
Jul	30	22	36	
Aug	29	19	20	
Sep	32	30	34	
Oct	27	31	36	
Nov	28	28	34	
Dec	23	29	30	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average





Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	8	5	
19/02/2022	6	5	
26/02/2022	9	10	
05/03/2022	8	11	
12/03/2022	6	7	
19/03/2022	9	7	
26/03/2022	8	4	
02/04/2022	7	10	
09/04/2022	7	6	
16/04/2022	6	4	
23/04/2022	10	5	
30/04/2022	8	3	


\* Average patients per year rounded to the nearest integer.

# GYNAECOLOGICAL CANCER

### CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-


2019 average -13.5%



Month first		Year first sa	ample taken	
sample taken	2017-2019*	2020	2021	2022
Jan	58	60	31	37
Feb	49	44	42	51
Mar	58	42	51	53
Apr	48	32	40	50
Мау	60	39	38	
Jun	60	41	55	
Jul	55	42	49	
Aug	56	38	64	
Sep	56	54	52	
Oct	58	59	48	
Nov	50	53	61	
Dec	49	48	59	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average

<sup>+3.7%</sup> 




Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	10	14	
19/02/2022	11	17	
26/02/2022	16	11	
05/03/2022	16	14	
12/03/2022	16	14	
19/03/2022	13	13	
26/03/2022	15	15	
02/04/2022	13	13	
09/04/2022	9	13	
16/04/2022	11	11	
23/04/2022	17	13	
30/04/2022	14	19	

\* Average patients per year rounded to the nearest integer.

# CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-


2019 average -12.5%



Month first		Year first sa	imple taken	
sample taken	2017-2019*	2020	2021	2022
Jan	31	31	22	27
Feb	22	20	41	22
Mar	23	20	30	30
Apr	27	12	26	17
Мау	30	15	23	
Jun	30	21	22	
Jul	25	31	23	
Aug	32	26	23	
Sep	30	23	25	
Oct	34	26	27	
Nov	32	30	23	
Dec	28	30	31	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average





Week first sample	Year first sam	ıple taken
taken**	2017-2019*	2022
12/02/2022	8	10
19/02/2022	5	7
26/02/2022	6	4
05/03/2022	6	8
12/03/2022	5	5
19/03/2022	5	3
26/03/2022	6	7
02/04/2022	9	9
09/04/2022	9	3
16/04/2022	5	10
23/04/2022	6	3
30/04/2022	8	4


\* Average patients per year rounded to the nearest integer.

# **URINARY CANCER**

### CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-


2019 average -10.4%



Month first		Year first sa	ample taken	
sample taken	2017-2019*	2020	2021	2022
Jan	57	52	45	49
Feb	58	41	34	43
Mar	53	47	53	55
Apr	55	27	43	44
Мау	52	39	60	
Jun	52	54	59	
Jul	46	56	52	
Aug	56	45	47	
Sep	48	44	39	
Oct	44	36	49	
Nov	49	48	48	
Dec	46	38	46	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average






Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	14	17	
19/02/2022	16	14	
26/02/2022	20	21	
05/03/2022	12	19	
12/03/2022	14	18	
19/03/2022	16	8	
26/03/2022	18	25	
02/04/2022	19	16	
09/04/2022	20	10	
16/04/2022	13	9	
23/04/2022	14	12	
30/04/2022	16	20	

\* Average patients per year rounded to the nearest integer.

# HAEMATOLOGICAL CANCER

### CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-




2019 average
+4.1%

Month first		Year first	sample taken	
sample taken	2017-2019*	2020	2021	2022
an	53	62	47	40
Feb	38	53	57	52
Mar	48	55	62	56
Apr	49	32	65	49
Мау	64	47	59	
lun	52	59	79	
ul	46	47	63	
Aug	50	50	53	
Sep	51	64	59	
Oct	62	48	45	
Nov	56	58	53	
Dec	53	55	42	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average





Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	8	12	
19/02/2022	10	13	
26/02/2022	11	12	
05/03/2022	13	8	
12/03/2022	10	18	
19/03/2022	9	7	
26/03/2022	16	16	
02/04/2022	13	11	
09/04/2022	14	11	
16/04/2022	11	19	
23/04/2022	12	6	
30/04/2022	12	13	


\* Average patients per year rounded to the nearest integer.

# MELANOMA

### CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin

Percentage change from March 2020 to April 2022 compared to expected number based on 2017-2019 average


-4.7%



Month first	Year first sample taken			
sample taken	2017-2019*	2020	2021	2022
Jan	24	40	24	35
Feb	28	30	18	30
Mar	27	37	29	36
Apr	28	17	32	31
Мау	32	14	31	
Jun	27	19	34	
Jul	32	19	27	
Aug	25	27	30	
Sep	32	24	35	
Oct	38	15	40	
Nov	37	34	50	
Dec	26	22	21	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average

<sup>+12.0%</sup> 



Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	8	9	
19/02/2022	8	7	
26/02/2022	8	12	
05/03/2022	7	5	
12/03/2022	7	12	
19/03/2022	7	12	
26/03/2022	7	7	
02/04/2022	6	7	
09/04/2022	10	9	
16/04/2022	6	7	
23/04/2022	8	4	
30/04/2022	10	12	


\* Average patients per year rounded to the nearest integer.

# NON-MELANOMA SKIN CANCER

# CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin


Percentage change from March 2020 to April 2022 compared to expected number based on 2017-

2019 average -20.9%



Month first	Year first sample taken			
sample taken	2017-2019*	2020	2021	2022
Jan	393	435	231	316
Feb	344	358	286	303
Mar	325	295	288	349
Apr	310	61	333	286
Мау	366	140	271	
Jun	367	244	339	
Jul	318	232	243	
Aug	344	238	249	
Sep	378	311	323	
Oct	401	305	318	
Nov	424	384	382	
Dec	304	268	271	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average



<sup>-1.3%</sup> 


Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	90	110	
19/02/2022	106	74	
26/02/2022	92	102	
05/03/2022	93	107	
12/03/2022	91	102	
19/03/2022	81	78	
26/03/2022	89	85	
02/04/2022	89	100	
09/04/2022	105	112	
16/04/2022	79	78	
23/04/2022	76	38	
30/04/2022	101	92	

\* Average patients per year rounded to the nearest integer.

# **OTHER CANCER**

### CHANGE IN NUMBER OF PATIENTS SINCE MARCH 2020 - Excluding Altnagelvin


Percentage change from March 2020 to April 2022 compared to expected number based on 2017-2019 average



Month first	Year first sample taken			
sample taken	2017-2019*	2020	2021	2022
Jan	78	66	74	73
Feb	61	65	60	70
Mar	64	70	83	82
Apr	63	39	66	58
Мау	66	55	85	
Jun	64	69	75	
Jul	69	80	73	
Aug	65	55	55	
Sep	68	97	68	
Oct	82	73	72	
Nov	72	66	77	
Dec	60	64	63	

Percentage change in the twelve weeks up to 30/04/2022 compared to expected number based on 2017-2019 average

<sup>+12.0%</sup> 



Week first sample	Year first sample taken		
taken**	2017-2019*	2022	
12/02/2022	14	24	
19/02/2022	19	10	
26/02/2022	15	19	
05/03/2022	20	28	
12/03/2022	17	25	
19/03/2022	15	11	
26/03/2022	16	23	
02/04/2022	15	20	
09/04/2022	16	19	
16/04/2022	17	20	
23/04/2022	19	9	
30/04/2022	17	16	

\* Average patients per year rounded to the nearest integer.

## 1. NMSC: Non-melanoma skin cancer

2. Data is sourced from the four NHS pathology laboratories in Northern Ireland (Altnagelvin, Antrim, Belfast, Craigavon), which is provided to the NI Cancer Registry on a monthly basis. It does not include information on pathology samples processed by private laboratories.

3. Figures represent the number of patients with pathology samples that indicated a malignant tumour and had this result coded and recorded by the end of April 2022. Due to potential reporting delays, pathology data from the month following April 2022 are used in compiling the presented results.

4. Assignment of week number is based upon a Sunday to Saturday week. The week ending label used in graphs and tables is based upon the date of the end of the week (a Saturday) in 2021-2022. This is compared with the equivalent Sunday-Saturday week in 2017-2019, although the actual date ending this week in 2017-2019 will differ.

5. Individual patients with cancer may have more than one pathology sample. A diagnosis of cancer may be a result of more than one procedure indicating cancer, for example a breast cancer diagnosis may be based upon a positive biopsy of the breast and then a separate positive dissection of a lymph node. Patients are thus only included once per cancer type unless they have had pathology samples separated by more than two years, thus a patient with samples in March and April of 2019 will be counted once (in the March 2019 count), while a patient with samples in April 2017 and May 2020 will be counted in both the April 2017 and May 2020 counts.

6. Cancer types are defined as follows:

Bowel cancer: Includes colon, rectum and rectosigmoid junction (ICD10 codes: C18-C20).

Lung cancer: Includes lung and trachea (ICD10 codes: C33-C34).

Breast cancer: Includes female breast only (ICD10 codes: C50).

Prostate cancer: (ICD10 codes: C61).

**Gynaecological cancer:** Includes uterus, ovary, cervix, vulva, vagina, placenta and other female genital (ICD10 codes: C51-C58).

Upper GI cancer: Includes oesophagus and stomach (ICD10 codes: C15, C16).

**Head and neck cancer:** Includes lip, tongue, mouth, parotid & salivary glands, tonsil, oropharynx, nasopharynx, pyriform sinus, hypopharynx, nasal cavity, middle ear, sinuses and larynx (ICD10 codes: C00-C14, C30-C32).

**Urinary cancer:** Includes kidney, renal pelvis, ureter, bladder and other urinary (ICD10 codes: C64-C68). **Haematological cancer:** Includes lymphoma (all types), leukaemia (all types), myeloma, malignant immunoproliferative disease and other lymphoid and haematopoietic (ICD10 codes: C81-C96). **Melanoma:** (ICD10 code: C43).

Non-melanoma skin cancer (NMSC): (ICD10 code: C44).

**Other cancer:** Includes cancers of small intestine, anus, liver, gallbladder, thymus, bone, mesothelioma, soft tissue, penis, testis, eye, brain, endocrine system and thyroid (ICD10 codes: C16, C21-C26, C37-C41, C45-C49, C60, C62, C63, C69-C75). Excludes cancer of unknown primary.